Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) was submitted on September 14, 2023, reporting events occurring on September 14 and September 15, 2023. The filing addresses significant changes to the Company's Board of Directors, specifically the resignation of the long-serving Chairman and the appointment of a new Chairman and director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation of Chairman: James N. Topper, M.D., Ph.D., resigned as Class II director and Chairman of the Board effective September 15, 2023. Dr. Topper served on the Board since 2007 and as Chairman since 2015. The resignation is not due to any disagreement with the Company.
- Advisory Role: Dr. Topper will remain in a transitionary advisory role to the Board through Q1 2024 under a new Advisory Agreement.
- Appointment of New Chairman: John Orwin was appointed as a Class II director, member of the Nominating and Corporate Governance Committee, and Chairman of the Board, effective September 15, 2023.
Compensation and Governance Details
In connection with his appointment, Mr. Orwin received the following compensation packages subject to continued service:
- Pro Rata Retainer: A stock option to purchase 3,311 shares at the closing price on September 15, 2023, vesting in full on January 6, 2024.
- Pro Rata Retainer (RSUs): 2,035 restricted stock units vesting in full at the 2024 annual meeting.
- Three-Year Grant (Options): A stock option to purchase 10,600 shares at the closing price on September 15, 2023, vesting monthly over three years.
- Three-Year Grant (RSUs): 3,900 restricted stock units vesting over a three-year period (one-third annually).
The Company entered into a standard indemnification agreement with Mr. Orwin. No family relationships or undisclosed material interests were reported.
Investor Verification Checklist
- Verify the effective date of Dr. Topper's resignation and the start of his advisory period.
- Confirm the vesting schedules and exercise prices for the stock options and RSUs granted to Mr. Orwin.
- Review the Company's subsequent filings for the election of a new CEO or other executive changes if not addressed in this report.
- Check the Nasdaq Global Market closing price on September 15, 2023, to determine the exercise price for the granted options.